NEWS | EVENTS | PRESENTATIONS
Chief Analytics Officer Slava Akmaev to Speak at BioData World
Akmaev to discuss how to accelerate clinical development with AI-driven approaches.
From Nature: Computer-Calculated Compounds
The aim of BERG’s approach is to identify potential treatments on the basis of the precise biological causes of disease.
EB Treatment Candidate BPM 31510 Granted Orphan Drug Designation in US
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BERG’s BPM 31510 (ubidecarenone), a treatment candidate for patients with epidermolysis bullosa (EB), the company announced.
How Big Pharma is Using AI to Make Better Drugs
BERG will use its bAIcis® platform to help AstraZeneca identify biological targets in the battle against Parkinson’s Disease.
AI is Helping Turn Tide Against Flu in Two Important Ways
CEO Niven R. Narain discusses AI as a game-changer in battle against the flu.
Flu Epidemic Could Cost Employers $9 Billion
BERG CEO Niven Narain discusses how BERG will help Sanofi improve its flu vaccine.
Flu-pocalypse? Why Scientists are Scrambling to Make 'Universal Influenza Vaccine'
BERG CEO Niven Narain explains to Fox Business News how BERG will help business partner Sanofi to improve its flu vaccines.
BERG Teams with Mass General Hospital, Brigham and Women's Hospital to Combat Alzheimer's Disease
BERG CEO Niven Narain talks with WBZ Radio's Jeff Brown about how BERG, Mass General Hospital and Brigham and Women's Hospital will work together to battle Alzheimer's Disease.
BERG, AstraZeneca Partnership Highlighted in Forbes Column
BERG and AstraZeneca will use AI to better understand -- and fight -- Parkinson's Disease and other neurological disorders.
BERG Helps Establish McLeod Research Fellowship at USUHS
The award will support an outstanding biomedical researcher to further accelerate the progress of ongoing prostate cancer research.
CEO Niven Narain Discusses Partnership with Sanofi Pasteur
CEO Niven Narain tells BBC 'World Business Report' about how partnership with Sanofi could bring about better flu vaccine.
BERG, Sanofi team up on AI-flu vaccine project
Biopharma and med-tech firm BERG is teaming up with Sanofi Pasteur to launch a new research effort that uses AI to try and improve flu vaccine outcomes.
Sanofi turns to artificial intelligence to beat flu
The French drugmaker Sanofi has teamed up with a US biotech group to use artificial intelligence in an effort to develop more effective flu vaccines.
BERG Supports PurpleStride 2017 in Fight Against Pancreatic Cancer
Employees, colleagues, family and friends of BERG will be participating in PurpleStride Boston 2017 to raise awareness and funds for pancreatic cancer research. Learn more.
CSO Ranga Sarangarajan, CAO Slava Akmaev explain how embrace of AI has led to promising drug candidates.
Sarangarajan notes that "AI provides an opportunity for understanding the data in avenues that a traditionally trained mind can't. We have our biases, but AI is purely data-driven."
CEO Niven Narain Sheds Light on New Prostate Cancer Diagnostic Test Developed for DoD
Narain discusses new prostate cancer diagnostic test developed for DoD, and how BERG uses AI to cut production time, cost of drug development.
CEO Niven Narain Discusses AI, AstraZeneca Partnership on BBC's "Talking Business"
In addition to discussing how artificial intelligence can improve the drug-development process, Narain talks about BERG's new collaboration with AstraZeneca.
AstraZeneca Teams Up with BERG to Tackle Neurological Disease
AstraZeneca is teaming up with US biology and technology company BERG to search for new drugs to treat Parkinson’s Disease and other neurological disorders, using artificial intelligence.
AstraZeneca taps AI for drug discovery in deal with BERG
AstraZeneca has forged a research collaboration with Boston-based BERG, a specialist in artificial intelligence for drug hunting, in the latest sign of big pharma’s interest in using supercomputers for drug discovery.
The Next Frontier for A.I.? Drug Research
BERG CEO Niven Narain explains to the Cheddar Network how patient biological data, AI guides our drug-development efforts.
Wall Street Journal: How AI Is Transforming Drug Creation
The Wall Street Journal's Daniela Hernandez talks to BERG's CEO Niven Narain about efforts to advance drug discovery through the use of AI.
Pharma–Advocacy Partnerships: How the BERG–debra Partnership Helps EB Patients
CEO Niven Narain discusses the Berg-debra of America partnership, and how patient input is critical to understanding a rare disease.
Frontline Genomics talks to Ranga Sarangarajan about our AI guided GBM trials
BERG's Chief Scientific Officer, Ranga Sarangarajan talks to Liz Harley at Frontline Genomics about our Phase I/II glioblastoma multiforme trials that are being guided by BERG's AI platform.
PharmExec.com discusses big data with BERG's Slava Akmaev
Slava Akmaev recently talked to Julian Upton at PharmaExec.com about the readiness of the biotech industry to adopt Big Data and analytics approaches to their work.
BD Taps BERG’s AI Platform to Reduce Medication Non-Adherence
HIT Consultant has published an article on BERG Analytics multi-year commercial agreement with Becton Dickinson to apply our AI platform bAIcis™ to BD/MedMined hospital data.
The Economist: Will artificial intelligence help to crack biology?
In the Economist, our CEO Niven R. Narain explains how BERG uses artificial intelligence to analyze tissue samples and clinical data to model and understand diseases and guide drug discovery.
An Industry Overdue for Disruption
Op ed in Drug Discovery & Development by Niven R Narain on the need to use technology to disrupt the current industry model of drug development.
BERG Wages Hope for Pancreatic Cancer
Employees, colleagues, family and friends of BERG will be participating in Purplestride Boston 2016 to raise awareness and funds for pancreatic cancer research. Click for more.
Tech.co: BERG Aims to Lower Cost of Medicine with Artificial Intelligence
Tech.co talks to Niven Narain about how BERG is aiming to reduce the costs associated with developing treatments by utilizing patient biology and artificial intelligence.
Frontline Genomics Talk to BERG's CEO Niven R. Narain
Liz Harley of Frontline Genomics sits down with BERG's CEO Niven R. Narain to discuss AACR and our approach to taking on cancer.
Fortune: Feature on BERG Clinical trials
Fortune has published a feature article about BERG and the announcement of our Phase II trials in pancreatic cancer.
Mendelspod talks to Niven R Narain, CEO
The Mendelspod podcast talked to BERG's CEO Niven R. Narain to discuss how BERG is flipping drug development upside down by examining patient biology with the help of AI.
Wired UK Feature on BERG
Wired UK has published a feature article profiling BERG and our CEO NIven R. Narain. The article will be in the April edition of WIRED UK. You can view the online article here: "The Startup Fighting Cancer with AI"
Bloomberg Radio - Taking Stock
Bloomberg Radio - Taking Stock talks to BERG's Co-Founder and CEO about precision medicine and our lead cancer therapeutic candidate BPM31510.
Bloomberg Advantage: Artificial Intelligence, Net Neutrality
The Bloomberg Advantage with Carol Massar and Cory Johnson sit down with Niven Narain Co-Founder and Chief Technology Officer of BERG
Biopharma Dive - The year Ahead: 11 Execs & Experts predict what's in store for biopharma in 2016
Biopharma Dive: The year Ahead: 11 Execs & Experts predict what's in store for biopharma in 2016. BERG's VP of systems medicine, Michael Kiebish offers his predictions and insight.
Huffington Post: Artificial Intelligence, What Will the Next 20 Years Bring?
Huffington Post offers its predictions for the future of Artificial Intelligence. BERG is cited as a leader in advancing the use of AI to make breakthrough drug discoveries.
HIT Consultant: Biotech Startup Hopes to Cure Cancer with Artificial Intelligence.
HIT Consultant covers BERG's approach to finding a cure for cancer.
BBC World News: Interview with Niven Narain
BBC World News interview with Niven Narain on how BERG is erupting the pharma industry by taking a new approach to drug discovery and development.
IBT: Real Healthcare Revolution Is Happening With Artificial intelligence
International Business Times features BERG as part of the revolutionary changes coming to healthcare.
Niven Narain Presents at Wired UK 2015
BERG's President and CTO, Niven R. Narain presented at the Wired UK 2015 talks: "When Technology Gets Ambitions".
The Telegraph UK: Cancer drug development time halved thanks to artificial intelligence
The Telegraph UK covers BERG's use of AI to discover and develop drugs in half the time of traditional pharma approaches.
Boston Business Journal: NIH partners with Berg to investigate it lead drug in Kidney Cancer
NIH partners with Framingham biotech to develop cancer drug.
Genomeweb: Berg, U of Miami Extend Cardiovascular Disease Collaboration
BERG, U of Miami Extend Cardiovascular Disease Collaboration.
Drug Discovery News: BERG Partners with University of Miami to Tackle Heart Disease
BERG Partners with University of Miami to Tackle Heart Disease.
IBT: Experts suggest Artificial Intelligence could treat individuals based on genes, history
Experts suggest Artificial Intelligence could treat individuals based on genes, history.
Popular Science: How Artificial Intelligence Can Make Drugs Better and Faster
Popular Science covers AI and it's potential to for faster less expensive drug discovery.
Fox Business: BERG Hopes Big Data Will Lead to Breakthrough for Pancreatic Cancer
Fox Business talks to Niven Narain about BERG's pancreatic cancer partnership Project Survival.
Niven Narain talks to Diedre Bolton of Fox Business: Risk & Reward about Project Survival
Diedre Bolton of Fox Business: Risk & Reward talked to Niven Narain about our partnership with BIDMC, PCRT and CRAB
Re/Code: Artificial Intelligence Raises New Hope for Cancer Patients
RE/Code: Explores the use of AI to help find cures for cancer including BERG's approach.
Fortune: How one company is using artificial intelligence to develop a cure for cancer.
Fortune: How one company is using artificial intelligence to develop a cure for cancer.
The Journal of Precision Medicine: A New Hope for Pancreatic Cancer
BERG is featured in the inaugural issue of the Journal of Precision Medicine
Boston Globe - Research initiative targets pancreatic cancer
Research initiative targets pancreatic cancer
Boston Business Journal - BERG seeks early signs of pancreatic cancer, the 'silent disease'
BERG seeks early signs of pancreatic cancer, the 'silent disease'
Fortune: An Audacious Attempt to Cure Pancreatic Cancer
Fortune features BERG's Pancreatic Cancer Partnership
NPR / WBUR - "Framingham Startup Uses Artificial Intelligence To Find Cancer Drugs"
WBUR and NPR's Curt Nickish discusses how BERG is using Artificial Intelligence and analytics to discover and develop cancer drugs.